Eltrombopag is a thrombopoietin agonist and has been used in aplastic anemia and post-transplantation thrombocytopenia. The c-MPL receptor is present on hematopoietic stem cells. There are no reports of eltrombopag utilization for improving poor graft function in the post-transplant setting. Here were report a case of a young female with post-transplant poor graft function as evident from the low absolute neutrophil count, anemia, and thrombocytopenia on day 60. Eltrombopag was started on day 72 and resulted in improvement in all 3 cell lines. The counts continued to be stable even after eltrombopag was discontinued. The patient tolerated the drug without significant side effects for 1 year.

Eltrombopag is a c-MPL receptor agonist drug [1-3]. Murine studies have shown that the thrombopoietin (TPO)/c-MPL receptor system is present in early hematopoiesis and hematopoietic stem cells (HSCs) [4]. There are few case reports of TPO agonist use in post-transplantation thrombocytopenia. Also, TPO agonist use has been suggested in the management of severe aplastic anemia. Here we report a case of eltrombopag utilization in the treatment of trilineage graft failure.

A 26-year-old female with acute myeloid leukemia developed marrow hypoplasia after 1 cycle of consolidation with high-dose cytarabine. This resulted in severe pancytopenia causing transfusion dependence for both red blood cells and platelets. Following persistence of pancytopenia for almost 5 months, she underwent a matched related (brother) allogeneic hematopoietic stem cell transplant using fludarabine/melphalan conditioning and alemtuzumab/tacrolimus as graft versus host disease prophylaxis. The patient had delayed engraftment as the absolute neutrophil count stayed below 1,000/µL (with granulocyte colony-stimulating factor support), hemoglobin was less than 8 g/dL, and the platelet count was less than 20,000/µL even at day 60. Bone marrow biopsy done on days 30 and 60 as well as at 1 year showed adequate cellularity, no evidence of relapse, and cytogenetics showed normal male karyotype. Chimerism studies showed 100% donor cells in myeloid lineage (CD33+) at days 30 and 60. Eltrombopag was started at 50 mg orally daily on day 72 to promote poor graft function. As shown in Figure 1, all 3 cell lines responded. The patient tolerated eltrombopag without any significant side effects. The patient was on eltrombopag for 1 year, and after that, it was stopped. Blood counts continued to be stable after discontinuing eltrombopag.

Fig. 1.

Three graphs showing the response to eltrombopag. The x axis shows the days after transplant.

Fig. 1.

Three graphs showing the response to eltrombopag. The x axis shows the days after transplant.

Close modal

Binding of TPO to the c-MPL receptor on megakaryocytes is the principal step that results in platelet maturation and release [1]. c-MPL is also expressed on the surface of HSCs [2-4]. Previous studies have shown that the addition of recombinant TPO leads to expansion of the pool of HSCs in culture [4]. In vitro models using knockout mice have shown that deficiency of c-MPL receptor [5, 6] or the TPO ligand leads to a reduced number of HSCs. Eventually, multilineage bone marrow failure develops [7]. These observations suggest that stimulation of c-MPL-signaling pathways may overcome depletion of HSCs and progenitor cells in aplastic anemia. Previous studies were done on cytokines like erythropoietin, and granulocyte colony-stimulating factor in aplastic anemia did not show a benefit because HSCs did not have receptors for these cytokines on them [8].

Romiplostim is a peptide TPO mimetic which activates the TPO receptor by binding to the distal hematopoietic receptor domain. Eltrombopag is a non-peptide TPO mimetic that activates the TPO receptor by binding to the transmembrane domain [9]. While romiplostim is given subcutaneously, eltrombopag can be given orally [9]. While romiplostim is only FDA approved for immune thrombocytopenia [10], eltrombopag is FDA approved for immune thrombocytopenia, hepatitis C-related thrombocytopenia, and severe aplastic anemia [11].

Previous studies have shown that both are useful in post-transplantation thrombocytopenia anemia [12-14] and aplastic anemia [15, 16]. To our knowledge, this is the first case of eltrombopag use for the treatment of trilineage graft failure after allogeneic stem cell transplant [17]. Our case highlights the use of eltrombopag as a very effective medication with minimal side effects to promote poor graft function after allogeneic hematopoietic stem cell transplant. Repeat biopsy done after 1 year did not show any signs of myelodysplasia, recurrent acute myeloid leukemia, or myelofibrosis. Like previous studies on aplastic anemia [6], in our patient, the response continued even after eltrombopag was stopped.

There is evidence that eltrombopag might be stimulating hematopoiesis in noncompetitive activation of c-MPL. In immune thrombocytopenia, TPO levels are at the upper end of average, while in aplastic anemia they are significantly elevated [18]. Eltrombopag binds outside the ligand-binding pocket at the membrane, spanning a region of c-MPL. It activated signaling by JAK-STAT (Janus-associated kinase-signal transducers and activators of transcription) and MAPK (mitogen-activated protein kinase) pathways [19].

Umbilical cord blood is emerging as a promising source of stem cells for allogeneic stem cell transplant, but it is challenged by low stem cell yield. In a previous study done on umbilical cord blood, eltrombopag enhanced expansion of HSCs in vivo and in vitro [5]. Also, eltrombopag favored earlier HSC populations which differed from recombinant TPO [20].

The authors have no ethical conflicts to disclose.

The authors have no conflicts of interest to declare.

1.
Kaushansky
K
.
Historical review: megakaryopoiesis and thrombopoiesis
.
Blood
.
2008
Feb
;
111
(
3
):
981
6
.
[PubMed]
0006-4971
2.
Kaushansky
K
,
Lin
N
,
Grossmann
A
,
Humes
J
,
Sprugel
KH
,
Broudy
VC
.
Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice
.
Exp Hematol
.
1996
Feb
;
24
(
2
):
265
9
.
[PubMed]
0301-472X
3.
Qian
H
,
Buza-Vidas
N
,
Hyland
CD
,
Jensen
CT
,
Antonchuk
J
,
Månsson
R
, et al.
Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells
.
Cell Stem Cell
.
2007
Dec
;
1
(
6
):
671
84
.
[PubMed]
1934-5909
4.
Zeigler
FC
,
de Sauvage
F
,
Widmer
HR
,
Keller
GA
,
Donahue
C
,
Schreiber
RD
, et al.
In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells
.
Blood
.
1994
Dec
;
84
(
12
):
4045
52
.
[PubMed]
0006-4971
5.
Alexander
WS
,
Roberts
AW
,
Nicola
NA
,
Li
R
,
Metcalf
D
.
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl
.
Blood
.
1996
Mar
;
87
(
6
):
2162
70
.
[PubMed]
0006-4971
6.
Kimura
S
,
Roberts
AW
,
Metcalf
D
,
Alexander
WS
.
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin
.
Proc Natl Acad Sci USA
.
1998
Feb
;
95
(
3
):
1195
200
.
[PubMed]
0027-8424
7.
Geddis
AE
.
Congenital amegakaryocytic thrombocytopenia
.
Pediatr Blood Cancer
.
2011
Aug
;
57
(
2
):
199
203
.
[PubMed]
1545-5009
8.
Gurion
R
,
Gafter-Gvili
A
,
Paul
M
,
Vidal
L
,
Ben-Bassat
I
,
Yeshurun
M
, et al.
Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis
.
Haematologica
.
2009
May
;
94
(
5
):
712
9
.
[PubMed]
0390-6078
9.
Kuter
DJ
.
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia
.
Annu Rev Med
.
2009
;
60
(
1
):
193
206
.
[PubMed]
0066-4219
10.
Nplate package insert FDA.
2011
.
11.
Promacta package insert FDA.
2015
.
12.
Hartranft
ME
,
Clemmons
AB
,
DeRemer
DL
,
Kota
V
.
Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients
.
J Oncol Pharm Pract
.
2017
Jan
;
23
(
1
):
10
7
.
[PubMed]
1078-1552
13.
Poon
LM
,
Di Stasi
A
,
Popat
U
,
Champlin
RE
,
Ciurea
SO
.
Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation
.
Am J Blood Res
.
2013
Aug
;
3
(
3
):
260
4
.
[PubMed]
2160-1992
14.
Olnes
MJ
,
Scheinberg
P
,
Calvo
KR
,
Desmond
R
,
Tang
Y
,
Dumitriu
B
, et al.
Eltrombopag and improved hematopoiesis in refractory aplastic anemia
.
N Engl J Med
.
2012
Jul
;
367
(
1
):
11
9
.
[PubMed]
0028-4793
15.
Lee
JW
, et al.
Efficacy and Safety of Romiplostim in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: 1-Year Interim Analysis of Phase 2 Clinical Trial
.
Blood
.
2016
;
128
(
22
):
3910
3910
.0006-4971
16.
Gill
H
,
Leung
GM
,
Lopes
D
,
Kwong
YL
.
The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia
.
Br J Haematol
.
2017
Mar
;
176
(
6
):
991
4
.
[PubMed]
0007-1048
17.
Dyba
J
,
Tinmouth
A
,
Bredeson
C
,
Matthews
J
,
Allan
DS
.
Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature
.
Transfus Med
.
2016
Jun
;
26
(
3
):
202
7
.
[PubMed]
0958-7578
18.
Emmons
RV
,
Reid
DM
,
Cohen
RL
,
Meng
G
,
Young
NS
,
Dunbar
CE
, et al.
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction
.
Blood
.
1996
May
;
87
(
10
):
4068
71
.
[PubMed]
0006-4971
19.
Erickson-Miller
CL
,
Delorme
E
,
Tian
SS
,
Hopson
CB
,
Landis
AJ
,
Valoret
EI
, et al.
Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist
.
Stem Cells
.
2009
Feb
;
27
(
2
):
424
30
.
[PubMed]
1066-5099
20.
Sun
H
,
Tsai
Y
,
Nowak
I
,
Liesveld
J
,
Chen
Y
.
Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis
.
Stem Cell Res (Amst)
.
2012
Sep
;
9
(
2
):
77
86
.
[PubMed]
1873-5061
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.